Brentuximab vedotin (hereafter referred to as brentuximab) is an antibody-drug conjugate of anti-CD30 monoclonal antibody combined with the anti-tubulin agent monomethyl auristatin E. It is approved for treatment of mycosis fungoides, Hodgkin’s lymphoma, and systemic anaplastic large cell lymphoma.3,4 Brentuximab has been associated with several potential adverse reactions; however, reports of renal complications have been rare.5 Here, we present a case of brentuximab-induced AIN. Here, TNFRSF8 is linked to mycosis fungoides.